Free Trial
→ 70%, 80%, 90% Win Rates? Grab Your Free Cheatsheets Today! (From WealthPress) (Ad)

Adverum Biotechnologies 11/4/2024 Earnings Report

Adverum Biotechnologies logo
$3.94 -0.04 (-1.01%)
As of 02/21/2025 04:00 PM Eastern
Earnings HistoryForecast

Adverum Biotechnologies EPS Results

Actual EPS
-$1.30
Consensus EPS
-$1.20
Beat/Miss
Missed by -$0.10
One Year Ago EPS
N/A

Adverum Biotechnologies Revenue Results

Actual Revenue
$1.00 million
Expected Revenue
$0.50 million
Beat/Miss
Beat by +$500.00 thousand
YoY Revenue Growth
N/A

Adverum Biotechnologies Announcement Details

Quarter
Date
11/4/2024
Time
After Market Closes

Conference Call Resources

Adverum Biotechnologies Earnings Headlines

3 US Penny Stocks With Market Caps Below $400M
February 19 at 2:14 AM | finance.yahoo.com
ADVM stock touches 52-week low at $3.95 amid sharp annual decline
February 13, 2025 | msn.com
The FED is losing the war on inflation
It's no longer just a “guesstimate” – Inflation is indeed getting worse. And although we want to believe the Fed has a good grip on it, they don't. Right now, the suits over there are caught between a rock and a hard place. Either they watch as inflation grows, or they tear it down and send us into a full-blown recession. The kicker here is that neither of these are good for you. Whichever pill we end up with, prices will still climb higher as the value of the dollar sinks lower. The only real way out for the regular person is to increase your earning power. By increasing your income to match prices as they flare up… You’ll stay ahead of the impending doom we're running face-first into. And if you're looking for a strategy to help increase your income in 2025… I've got just the thing for you! You see, last year, I was able to grow a $10k model account to a little over $63k with 100 trade alerts But I changed my trading rules and more than doubled my results on those 100 published trades. I'm now calling them Warped Options…
February 22, 2025 | WealthPress (Ad)
4D Molecular’s wAMD drug is best-in-class, says RBC, sees ‘ideal’ entry point
February 11, 2025 | markets.businessinsider.com
Adverum Biotechnologies to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
February 5, 2025 | globenewswire.com
ADVM stock touches 52-week low at $4.01 amid market challenges
February 4, 2025 | msn.com
See More Adverum Biotechnologies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Adverum Biotechnologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Adverum Biotechnologies and other key companies, straight to your email.

About Adverum Biotechnologies

Adverum Biotechnologies (NASDAQ:ADVM), a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.

View Adverum Biotechnologies Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles